ArticleTherapeutic advances in medical oncology2020
The role of adjuvant chemotherapy in stage I-III male breast cancer: a SEER-based analysis.
Article in Therapeutic advances in medical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 15 citations in OpenAlex.
- The applicability of the 21-gene assay to inform chemotherapy benefit in lymph node positive hormone receptor positive male breast cancer.Breast cancer research and treatment · 2026Article
- Development and validation of an online prognostic risk stratification tool to assist decisions on perioperative chemotherapy for men with luminal early breast cancer.Breast cancer research : BCR · 2026Article
- The Effect of Clinicopathological Features and Postoperative Management on Prognosis in Male Breast Cancer.The breast journal · 2026Article
- Development and Validation of a Prognostic Nomogram Model for HER2-Positive Male Breast Cancer Patients.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- The features of male breast cancer in China: A real-world study.Breast (Edinburgh, Scotland) · 2024Article
- Male Breast Cancer: An Updated Review of Patient Characteristics, Genetics, and Outcome.International journal of breast cancer · 2024Review
- Article
- A Novel Method for Dynamically Assessing the Prognosis of Patients with pT1 Gastric Cancer: A Large Population-Based Dynamic Prognostic Analysis.Journal of oncology · 2023Article
- A Prospective Population-Based Study of Cardiovascular Disease Mortality following Treatment for Breast Cancer among Men in the United States, 2000-2019.Current oncology (Toronto, Ont.) · 2022Article
- The beneficial role of Asian-based RecurIndex test in the prognostic prediction in Chinese male breast cancer patients.Scientific reports · 2021Article
- An introduction to male breast cancer for urologists: epidemiology, diagnosis, principles of treatment, and special situations.International braz j urol : official journal of the Brazilian Society of UrologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsMale breast cancer is an uncommon disease. The benefit of adjuvant chemotherapy in the treatment of male breast cancer patients has not been determined. The aim of this study was to explore the value of adjuvant chemotherapy in men with stage I-III breast cancer, and we hypothesized that some male patients may safely skip adjuvant chemotherapy.
methodsMale breast cancer patients between 2010 and 2015 from the Surveillance Epidemiology and End Results database were included. Univariate and multivariate Cox analyses were used to analyse the factors associated with survival. The propensity score matching method was adopted to balance baseline characteristics. Kaplan-Meier curves were used to evaluate the impacts of adjuvant chemotherapy on survival. The primary endpoint was survival.
resultsWe enrolled 514 patients for this study, including 257 patients treated with chemotherapy and 257 patients without. There was a significant difference in overall survival (OS) but not in breast cancer-specific survival (BCSS) between the two groups (
conclusionFor stage I and stage IIA patients, adjuvant chemotherapy could not improve OS and BCSS. Therefore, adjuvant chemotherapy might be skipped for stage I and stage IIA male breast cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.